Bodenhoff Mads
Known title: SVP & PAOCIK: 0002014697
Associated companies
Transaction History
| ASND | ▲ Buy | Option Exercise | 3,000 | $330K | 9/8/2026 | View on chart |
| ASND | ▼ Sell | Open Market | 3,000 | $811K | 9/8/2026 | View on chart |
| ASND | ▲ Buy | Option Exercise | 3,000 | $330K | 9/8/2026 | View on chart |
| ASND | ▼ Sell | Open Market | 3,000 | $811K | 9/8/2026 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Ascendis Pharma signs BioMarin license deal, ends litigation
Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.
Ascendis Pharma signs BioMarin license deal, ends litigation. Ascendis Pharma has reached a licensing agreement with BioMarin for its TransCon Cnp, Navepegritide, and Yuviwel products. Under the deal, Ascendis will pay royalties on sales in the U.S. and Europe until May 2030, and all pending legal disputes between the two companies have been dismissed. This resolution removes a significant legal uncertainty for the stock, which is currently trading near its 52-week low.